Samsung Biologics America, a subsidiary of Samsing Biologics, a CDMO, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK for $280 million. This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site.

Located in Rockville, Maryland, the facility encompasses two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity, supporting both clinical and commercial production from small to large scale. Existing products will continue to be manufactured at the site, and Samsung Biologics plans to make additional investments to expand the site’s capacity and upgrade technology to further support a more resilient U.S. supply chain for critical biologic medicines.

Closing is anticipated toward the end of Q1 of 2026. The company will also retain more than 500 employees at the site to ensure operational continuity and stability. By integrating this facility into its global network, Samsung Biologics will provide clients with flexible, multi-site options in both the U.S. and Korea to ensure that live-saving therapeutics are reliably available to American patients.

“This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics,” said John Rim, CEO and President of Samsung Biologics. “This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.